Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

Why CRISPR Therapeutics’ stock gained around $8 today

February 25, 2019 0

CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter …

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91

February 25, 2019 0

We congratulate our subscribers who kept Spark Therapeutics (ONCE) in spite of the stock’s kind of paralysis for no …

Cytokinetics’ heart failure drug omecamtiv mecarbil advancing into late phase trials

February 23, 2019 0

Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

February 21, 2019 0

Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Nektar presentation today at the ASCO genitourinary cancers symposium

February 15, 2019 0

Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at …

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

February 15, 2019 0

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …

Exelixis’ excellent scientific and financial accomplishments

February 13, 2019 0

Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …

Portola: On the right track

February 12, 2019 0

Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in …

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

February 11, 2019 0

The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

ImmunoGen’s Report and Standing. Why Biogen Is Experiencing a Selloff

February 8, 2019 0

ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) …

Halozyme signs another license agreement this time with argenx

February 5, 2019 0

Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

February 1, 2019 0

FDA Granted Rare Pediatric Disease Designation for RegenxBio’s Product RGX-181 for CLN2 RegenxBio RegenxBio (RGNX), a …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Good news and setbacks during the departed week

Why CRISPR Therapeutics’ stock gained around $8 today

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91

Cytokinetics’ heart failure drug omecamtiv mecarbil advancing into late phase trials

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

The Week in Review #37

Nektar presentation today at the ASCO genitourinary cancers symposium

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

Exelixis’ excellent scientific and financial accomplishments

Portola: On the right track

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

End of the Year Decisions ~ Part 3

ImmunoGen’s Report and Standing. Why Biogen Is Experiencing a Selloff

Halozyme signs another license agreement this time with argenx

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

Merck’s superior accomplishments

Agenus fincances through Tokenization. Amgen’s critics hit hard. Why BioTime could thrive on OncoCyte news

OncoCyte liquid biopsy proves its accuracy and superiority in the differential diagnoses of Lung Cancer

Now You See It, Now You Don’t

End of the Year Decisions Part 2